\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={Different Recent, New and Old Approaches Could Help us to Win the Game against SARS-COV-2},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{2022 1970-01-01 (revised: 5 Year 2022 01 January 1970)}
\def\TheID{\makeatother }
\def\TheDate{2022 1970-01-01}
\title{Different Recent, New and Old Approaches Could Help us to Win the Game against SARS-COV-2}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \author[1]{Amro A.  Amara}

\renewcommand\Authands{ and }

\date{\small \em Received: 1 January 1970 Accepted: 1 January 1970 Published: 1 January 1970}

\maketitle


\begin{abstract}
        


SARS-COV-2 is a virus that has led to the death of a large number of persons, and caused a global endemic problem since December 2019. Vaccines have been prepared, and authorized in an argent way to survive lives. Any possible or known tactic has been used to prevent its spreading, treat infected individual, and to understand how it changes its structure to produce, in advance, a pre-made vaccine that could be used in an adequate time. Understanding their antigenIcity, mutation, adaptation, different types of the produced vaccines, its in cito interaction, and the like, are essential to win the battle. Humanity has been winning the battle against some more virulence viruses like smallpox (human virus), and the Rinderpest (animal virus) using strategies that could only describe nowadays as a ?simple method.?. This review is concerned with highlighting important issues concerning SARS-COV-2, and its vaccine(s), structure, epitopes, RNA, surface antigens, personalizing the individual different responses, the need for case-by-case treatments, and the like.

\end{abstract}


\keywords{SARS-COV-2; treatment personalization; epitopes; vaccine; control strategies.}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\begin{textblock*}{10cm}(1.05cm,3cm)
{{\textit{CrossRef DOI of original article:}} \underline{}}
\end{textblock*}\let\tabcellsep& 	 	 		 
\section[{Introduction}]{Introduction}\par
espiration is the process of absorbing oxygen and expelling carbon dioxide. Respiration is a delicate, and vital process. A few minutes without oxygen can result in death or critical deterioration of the brain in a human. The majority of the oxygen in the body is bound to hemoglobin, which is made up of four ironcontaining ring structures (hemes) that are chemically attached to a large protein (globin). Each iron atom can bind, and then release an oxygen molecule. Carbon dioxide transport in the blood is far more complicated \hyperref[b36]{(Klocke 2013}). One of the serious attackers to the respiratory organ is the SARS virus. SARS refers to the severe acute respiratory syndrome, while SARS-CoV refers to severe acute respiratory syndrome coronavirus. Corona viruses (CoV) are the primary etiologic agents of the common cold. It causes outbreaks, and pandemics. In general, corona viruses cause disease in humans, other mammals, and birds. In humans, it causes Author: Protein Research Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab City, P.O. Box 21934 Alexandria, Egypt. e-mails: amroamara@web.de, aamara@srtacity.sci.eg respiratory, and intestinal disease. Severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and the recent rapidly progressing COVID-19 caused by SARS-CoV-2 are examples. SARS-Cov-1 has infected more than 8,000 people in 32 countries, and caused about 10\% death \hyperref[b17]{(Cavanagh and Britton 2008)}. SARSr-CoV refers to one of many viruses similar to SARS-CoV-1, and SARS-CoV-2. No other SARSr-CoV virus has infected humans or caused severe illness like SARS-CoV-1, and SARS-CoV-2. Bats are important reservoir hosts for many SARSr-CoV strains. Several strains have been identified in palm civet. More than 600 million COVID-19 cases, and 6.5 million fatalities have been reported globally as of August 31, 2022  {\ref (Low, Zabidi et al. 2022}). To avoid confusion, it is recommended to use the numbers behind SARS-CoV to distinguish between the two important viruses SARS-CoV-1, and SARSr-CoV-2. The severe acute respiratory syndrome coronavirus SARS-CoV (old name) or SARS-CoV-1 (new name), is generated severe acute respiratory syndrome (SARS) epidemic in 2002-2004. The severe acute respiratory syndrome coronavirus virus 2 (SARS-CoV-2) is causing the ongoing COVID-19 pandemic. SARS virus's virions have a buoyant density of approximately 1.18 g ml-1 in sucrose \hyperref[b17]{(Cavanagh and Britton 2008)}. Corona viruses do not necessarily respect species barriers. The deadly spread of severe acute respiratory syndrome (SARS) coronavirus is reported among wildlife, and humans. As a group, corona viruses are not confined to specific organs. Target tissues could include the nervous, immune, renal, and re-productive systems, as well as many parts of the respiratory, and intestinal systems \hyperref[b17]{(Cavanagh and Britton 2008)}. Triggering the spike proteins resulting in the formation of neutralizing anti-bodies, and T-cell responses  {\ref (Kantarcioglu, Iqbal et al. 2022}). Coronaviruses share four structural proteins. They are 1) a high surface area glycoprotein (S about 1150-1450 amino acids); 2) a small envelope protein (E. about 100 amino acids, present in small amounts in virions); 3) integral membrane glycoprotein (M about 250 amino acids), and 4) a phosphorylated nucleocapsid protein (N about 500 amino acids). Group 2a viruses have an additional structural glycoprotein, the protein hemagglutinin esterase (HE; approximately 425 amino acids) \hyperref[b17]{(Cavanagh and Britton 2008)}. 
\section[{II.}]{II.} 
\section[{Vaccine}]{Vaccine}\par
The early studies on vaccines against the COVID-19 virus have targeted the viral spike (S) protein.\par
Antibodies targeting M (membrane), and E (envelope) proteins have failed to neutralize the COVID-19 infection. The N (nucleocapsid) protein is highly immunogenic, and can elicit robust humoral, and cellular immune responses. The most interesting one is the viral spike (S) protein. The antibodies attach to the viral spike protein (S), and prevent it from binding to the human angiotensin-converting enzyme-2 receptor (ACE2 receptor). This enzyme is essential for the virus to enter the cell. Protein S is a fusion glycoprotein divided into two functionally distinct parts (S1, and S2). S1 is found on the surface of the virus, and contains the receptorbinding domain (RBD) which specifically binds to the host cell receptor. The S2 transmembrane domain contains the fusion peptide, which mediates the fusion of viral, and cell membranes  {\ref (Sharma, Sultan et}  Mutations in the S RBD protein-coding regions may be variants with increased rates of transmission, severity, mortality, and reduced susceptibility to monoclonal or polyclonal antibodies produced in response to infection or vaccination, and fraud in the diagnosis of the virus  {\ref (Singh, Pandit et al. 2021}). There are many considerations for people with special health conditions, such as pregnant women (Juan et al., 2020), and immunocompromised patients (Wang, Berger, \& Xu, 2021). In general, vaccinating people with specific health problems is still under study. See \hyperref[b35]{Kantarcioglu et al., (2022)}, and the references therein for details  {\ref (Kantarcioglu, Iqbal et al. 2022)}.\par
The innate immune system function as the first line of the host defines against SARS-CoV-2. Innate immune responses limit viral entry. It interferes with its essential replication pathways including translation and assembly. It helps to identify, and remove infected cells, coordinates, and accelerates the development of adaptive immunity. Cell surface, endosomal, and cytosolic pattern recognition receptors (PRRs) respond to pathogen-associated molecular patterns (PAMPs). They trigger inflammatory responses, and programmed cell death. In general, in-nate immunity limits viral infection, and promote clearance. However, excessive immune activation can lead to systemic inflammation, and severe disease. One should highlight that, acquiring common cold viruses, moderate corona virus, or even other reparatory virus infections naturally will build immunity that will react in less severity against CoV IV. 
\section[{Epitope in mRNA Vaccines}]{Epitope in mRNA Vaccines}\par
With the appearance of SARS-CoV-2 variants that harbor mutations in critical epitopes, the risk of eroding adaptive immunity elicited by either vaccination or prior infection as a result of this antigenic evolution increased. The identified epitopes in the COVID-19 mRNA vaccine may form the basis for further research on immune escape, viral variants, and the design of vaccine, and therapy. Mutation panel assays targeting the viral variants of concern demonstrated that the epitope variety induced by the mRNA vaccine is rich in breadth, and thus, can grant resistance against viral evolutionary escapes of the future, which represents an ad-vantage of vaccine-induced immunity. mRNA vaccination against SARS-CoV-2 elicited antibodies targeting viral spike RBD that have a broader distribution across RBD than natural infection-induced antibodies, which seem to offer more resistance against future SARS-CoV-2 evolutionary escapes (El-Baky and Amara 2022).\par
V. 
\section[{Some Proposed Strategies a) Proposed approach No. (1;): Activate the immune system with similar viruses (e.g., smallpox)}]{Some Proposed Strategies a) Proposed approach No. (1;): Activate the immune system with similar viruses (e.g., smallpox)}\par
The concept of using similar safe virus to vaccines against another virulence one is well known to the immunologist. Close, safe viruses could satisfy the demand for protecting against dangerous ones by activating the immune system, and producing antibodies that could neutralize them. Perhaps the most famous example is smallpox. The modern vaccine technology starts with simple observation, which has been well known among farmers but less explained until a physician explains it. The milkmaid which has been infected in their hand by cowpox is known that she becomes protected against smallpox. She has been happy because her face will be beautiful. She starts to song, and a physician hears this song "I shall never have smallpox for I have had cowpox. I shall never have an ugly pockmarked face." The cow's name is "Blossom". The physician started to investigate the case, and then he concluded that the infection with cowpox will protect against smallpox. He made manual infection from arm to arm by the cow lymph node (Amara 2016). In similar thinking, recently Fage et al. (202 2) reported that the existence of SARS-CoV-2 with other viruses that infect the respiratory organ could help in its control  {\ref (Fage, Hénaut et al. 2022)}. Because of the small number of co-infection cases reported since the start of the pandemic, the types of interactions between SARS-CoV-2, and other respiratory viruses are poorly understood. During concurrent infection, SARS-CoV-2 interferes with RSV-A2 replication but not A(H1N1)pdm09 replication. They are both respiratory viruses. Prior infection with A(H1N1)pdm09 reduces SARS-CoV-2 replication. According to \hyperref[b28]{Fage et al. (2022)} the mechanism involved in the viral interference between SARS-CoV-2, and A(H1N1)pdm09 is mediated by the production of interferon  {\ref (Fage, Hénaut et al. 2022)}. This approach, which, has been an old tactic and has been used since smallpox (treated by cowpox). 
\section[{b) Proposed approach No. (2): Attenuating the virus}]{b) Proposed approach No. (2): Attenuating the virus}\par
strain (e.g., Rabies) Pierre-Victor Galtier (1846-1908) a veterinarian, a student of Chauveau at the Lyons veterinary school (France). He demonstrated rabies to be an affectionateness of the nervous system, with a variable incubation period. In 1879, he evoked that laboratory dogs could be replaced by rabbits. In 1881, and 1882, Louis Pasteur, and his students Charles Chamberland, Emile Roux, and Louis Thuillier entered the fray. They modified Galtier's technique by inoculating nervous tissue from a rabid animal directly into the brain after trephination. By successive passages in dogs, they obtained a virus of maximal virulence coupled. The process was a with fixed incubation period of around ten days. To attenuate the virus virulence they, changing that host species. That has achieved indirectly by passages through rabbits. Emile Roux made up the selected attenuation procedure. It consisted of suspending the spinal cord of a rabid rabbit in a flask, in a warm dry atmosphere, as a process for slow desiccation. Using animals as alive propagating medium, Pasteur, and his group succeeded in producing 'attenuated viruses of different strengths'. A standardized range of viruses have been prepared and used to prepare a vaccine \hyperref[b29]{(Habel 1956} {\ref , Lombard, Pastoret et al. 2007}, Amara 2016). One should observe that the attenuated virus is used as a vaccine in the time of the activity of the virulence virus. 
\section[{c) Proposed approach No. (3): Use partially fragmented virus (e.g., Rinderpest)}]{c) Proposed approach No. (3): Use partially fragmented virus (e.g., Rinderpest)}\par
Rinderpest is a fatal disease has been known since time immemorial in Europe, and Central Asia with mortality range from 90 to 100\%. Rinderpest or the Cattle plague (also steppe murrain) caused by Rinderpest virus (group V ((-) ssRNA. It comprises among the great historical besets that cause destroyed human farm animals (Barrett, Pastoret et al., Pastoret and Jones 2004, Amara 2016). Robert Koch is the owner of the first publication of the practical method of immunizing cattle against the Rinderpest infections. He injects the uninfected animal with the bile of the animal that died by the Rinderpest, and after that with the serum of an immunized animal. After many trails, from the different researchers, Robert Koch, doing work in South Africa, recommended that cows could be saved by subcutaneous injection of blood serum, from immunized animals, and bile, from an infected animal. This unsafe formula has been shortly substituted by the employ of immune serum, and later on by mixing of immune serum, and virulent virus. Afterward, the method has been improved by consecutive passages of the bovine virus through goats, which enabled Edwards to produce a compromised vaccine in India in the 1920s. Runs with inactivated vaccines as well occurred. Afterward, the successful isolation of the virus in cell culture led to the in vitro developing of a weakened strain, and from this the production of a safe, and highly efficient vaccine  {\ref (} Evacuating viruses from their genomic material, and keeping their 3D structure unattached is a new approach. Newcastle virus has been prepared as a ghost virus by its evacuation from its RNA using H2O2 in concentration has given the name "bio-critical concentration" while it is the concentration, which has been used to evacuate E. coli. Few studies have been conducted on this promising approach. The unique point is that a cocktail of the viruses are expected to satisfy the demand of the immune system to confer correct immunization can be applied into H2O2 biocritical concentration to turn them to virus ghosts. Interestingly, the first simple study to evacuate the Newcastle virus has recommended the use of H2O2 as a virus deactivator, that has been recommended by many authors. H2O2 is a potent active chemical compound that can oxidize/degrade cell macromolecules, including the genomic DNA, RNA, and plasmids. The idea is to calculate the H2O2 concentration that could degrade the genetic material (even after time) but keep the virus 3D structure including its surface antigen, in the correct form. This approach has been used to evacuate, viruses, bacteria, e) Proposed approach No. (  {\ref 5}): Probiotics that produce antiviral compounds H2O2 exhibits antimicrobial activity against yeast, Gram-positive, and Gram-negative bacteria  {\ref (Suskovich, Kos et al. 2010)}. Some beneficial microbes produce H2O2 under aerobic conditions of growth. They release it into the environment to protect themselves \hyperref[b23]{(Daeschel 1989}). Among the other postulated pro-biotic mechanisms engaged in host protection or amelioration of viral respiratory diseases, the significant roles are reported to: reinforce, and protect the mucosal barrier; to stimulate forming antimicrobial compounds (e.g., H2O2)  {\ref (Balta, Butucel et al. 2021)}.\par
Probiotics, prebiotics, phytobiotics, and natural antimicrobials, including their metabolites, have received significant attention, mainly due to the SARS-CoV-2 pandemic, and are continuously tested for their ability to inhibit viruses, and pre-vent their pathogenic impact on the host  {\ref (}  
\section[{VI.}]{VI.} 
\section[{Future Prospective}]{Future Prospective}\par
It is becomes clear that even with the massive development in the science, and technology in different fields that, we still know much less. A virus that could not replicate, seen only under high magnification using the electron microscope, could pain us a lot. Even so, it is also proving that the world has become a big village. A respective amount of basic science becomes available for every person. The transfer of knowledge is so fast. Many respective institutions, and organizations that get the responsibility, companies that produce the different vaccines, and political makers that take the designs. So, what could be introduced in the future? There is a need for epitopes, and antigens databases, more fast protocol for personalizing the treatments, and more funds for the research and the researchers. There is a need for collecting experts worldwide in groups to exchange knowledge. In fact, there is a need to link the scientific institutions with the industry in a correct way that does not waste the time of the scientists or the money of the companies. The physical control of the movement, and the personal contacts, hygiene, the contact with the animals, particularly the wild animals, the patients' living conditions in the hospitals, and the like, should be revaluated, and readjusted. 
\section[{VII.}]{VII.} 
\section[{Conclusions}]{Conclusions}\par
This review is concerned with highlighting the most crucial point concerning SARA-COV-2, its nomenclature system, structure, antigenicity, epitopes, variants, different developed vaccines, the response of the personae with health issues, some strategies that succeeded with other viruses, some in natural treatments (e.g., probiotics), some points about the role of the innate immunity, and new idea for virus evacuation (virus ghost). The review gives the message for searching inside, and outside the immunity box. The simple introduced tactic might help in cases such that the vaccines production did not satisfy the global demand, in case of emergency or natural catastrophe, and the like.     \begin{figure}[htbp]
\noindent\textbf{} \par 
\begin{longtable}{P{0.85\textwidth}}
Kantarcioglu et al. (2022) reported that most vaccines made for SARS-CoV-2 (COVID-19) contain the viral spike protein. They are including whole virus vac-cines, viral vector vaccines, RNA vaccines, DNA vaccines, and their hybrid forms. COVID-19 variants cause various pathological responses, some of which may be resistant to antibodies generated by current vaccines (Kantarcioglu, Iqbal et al. 2022). These vaccines have been tested on many subjects, including young children, immunocompromised patients, pregnant subjects, and other specialized groups (Kantarcioglu, Most symptoms are mild, with a significant subset developing severe diseases ranging from pneumonia, and acute respiratory distress syndrome (ARDS), and multiple organ failure (MOF) (Hu, Guo et al. 2020, V'kovski, Kratzel et al. 2020, Zhou, Yang et al. 2020, Kantarcioglu, Iqbal et al. 2022). The vaccine used has been ap-proved in emergency procedures. They are approved for emergency use (Kantarcioglu, Iqbal et al. 2022). Kantarcioglu et al. (2022) reported that only the Pfizer vaccine has been fully approved by the US FDA (2021) (Kantarcioglu, Iqbal et al. 2022). The vaccine can generate neutralizing antibodies (Kantarcioglu, Iqbal et al. 2022).\end{longtable} \par
 
\caption{\label{tab_0}}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{} \par 
\begin{longtable}{P{0.85\textwidth}}
al. 2020,\\
Lee, Kim et al. 2021, Kantarcioglu, Iqbal et al. 2022).\\
The WHO reported that 296 candidate vaccines\end{longtable} \par
  {\small\itshape [Note: against COVID-19 had been developed, 112 in clinical trials, and 184 in preclinical trials (WHO. 2021). Vaccines developed include attenuated or inactivated whole virus vaccines, replicating/non-replicating virus vector vaccines, DNA, and mRNA-based vaccines, and recombinant or modified protein (subunit protein, virus-like particles)(Chung,  ]} 
\caption{\label{tab_1}}\end{figure}
 			\footnote{© 2022 Global Journals Different Recent, New and Old Approaches Could Help us to Win the Game against SARS-COV-2} 		 		\backmatter  			  				\begin{bibitemlist}{1}
\bibitem[Lombard ()]{b42}\label{b42} 	 		‘A brief history of vaccines and vaccination’.  		 			M Lombard 		.  	 	 		\textit{Revue Scientifique et Technique de l'OIE}  		2007. 26  (1)  p. .  	 
\bibitem[Zhou ()]{b61}\label{b61} 	 		‘A pneumonia outbreak associated with a new coronavirus of probable bat origin’.  		 			P Zhou 		.  	 	 		\textit{Nature}  		2020. 579  (7798)  p. .  	 
\bibitem[Sharma ()]{b50}\label{b50} 	 		‘A Review of the Progress and Challenges of Developing a Vaccine for COVID-19’.  		 			O Sharma 		.  	 	 		\textit{Frontiers in Immunology}  		2020. 11.  	 
\bibitem[Yang ()]{b60}\label{b60} 	 		‘A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity’.  		 			J Yang 		.  	 	 		\textit{Nature}  		2020. 586  (7830)  p. .  	 
\bibitem[Lee ()]{b39}\label{b39} 	 		‘Addition of probiotics to antibiotics improves the clinical course of pneumonia in young people without comorbidities: A randomized controlled trial’.  		 			C H Lee 		.  	 	 		\textit{Sci. Rep}  		2021. 11 p. 926.  	 
\bibitem[Müller ()]{b46}\label{b46} 	 		\textit{Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination},  		 			L Müller 		.  		2021.  		 			Cold Spring Harbor Laboratory 		 	 
\bibitem[Kantarcioglu ()]{b35}\label{b35} 	 		‘An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations’.  		 			B Kantarcioglu 		.  	 	 		\textit{Clinical and Applied Thrombosis}  		2022. 28 p. 107602962110566.  	 	 (Hemostasis) 
\bibitem[Ebinger ()]{b25}\label{b25} 	 		‘Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2’.  		 			J E Ebinger 		.  	 	 		\textit{Nature Medicine}  		2021. 27  (6)  p. .  	 
\bibitem[Suskovich ()]{b53}\label{b53} 	 		‘Antimicrobial Activity -The Most Important Property of Probiotic and Starter Lactic Acid Bacteria’.  		 			J Suskovich 		.  	 	 		\textit{Food Technol. Biotechnol}  		2010. 48  (3)  p. .  	 
\bibitem[Daeschel ()]{b23}\label{b23} 	 		‘Antimicrobial substances from lactic acid bacteria for use as food preservatives’.  		 			M A Daeschel 		.  	 	 		\textit{Food Technol}  		1989. 43  (1)  p. 164.  	 
\bibitem[Aarti ()]{b0}\label{b0} 	 		‘Antimycobacterium, anticancer, and antiviral properties of probiotics: An overview’.  		 			C Aarti 		.  	 	 		\textit{Microbes and Infectious Diseases},  				2020. 0 p. .  	 
\bibitem[Ettorre ()]{b22}\label{b22} 	 		‘Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19’.  		 			G Ettorre 		.  	 	 		\textit{Frontiers in Medicine}  		2020. 7.  	 
\bibitem[Wu and Mcgoogan ()]{b59}\label{b59} 	 		‘Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China’.  		 			Z Wu 		,  		 			J M Mcgoogan 		.  	 	 		\textit{JAMA}  		2020. 323  (13)  p. 1239.  	 
\bibitem[Hu ()]{b32}\label{b32} 	 		‘Characteristics of SARS-CoV-2 and COVID-19’.  		 			B Hu 		.  	 	 		\textit{Nature Reviews Microbiology}  		2020. 19  (3)  p. .  	 
\bibitem[Huang ()]{b33}\label{b33} 	 		‘Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China’.  		 			C Huang 		.  	 	 		\textit{The Lancet}  		2020. 10223. 395 p. .  	 
\bibitem[V'kovski ()]{b54}\label{b54} 	 		‘Coronavirus biology and replication: implications for SARS-CoV-2’.  		 			P V'kovski 		.  	 	 		\textit{Nature Reviews Microbiology}  		2020. 19  (3)  p. .  	 
\bibitem[Cavanagh and Britton ()]{b17}\label{b17} 	 		‘Coronaviruses: General Features’.  		 			D Cavanagh 		,  		 			P Britton 		.  	 	 		\textit{Encyclopedia of Virology},  				 			B W J Mahy,  			M H V Van-Regenmortel 		 (ed.)  		 (USA)  		2008. Elsevier Inc. p. .  	 	 (Third edition) 
\bibitem[Chung ()]{b21}\label{b21} 	 		‘COVID-19 Vaccine Frontrunners and Their Nanotechnology Design’.  		 			Y H Chung 		.  	 	 		\textit{ACS Nano}  		2020. 14  (10)  p. .  	 
\bibitem[COVID-19 vaccine tracker and landscape (2021)]{b57}\label{b57} 	 		\textit{COVID-19 vaccine tracker and landscape},  		 \url{https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidatevaccines}  		2021. August 2021. 20.  	 
\bibitem[Lee ()]{b40}\label{b40} 	 		‘Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages’.  		 			P Lee 		.  	 	 		\textit{Immune Network}  		2021. 21  (1) .  	 
\bibitem[El-Baky and Amara ()]{b26}\label{b26} 	 		‘Depending on Epitope Profile of COVID-19 mRNA Vaccine Recipients: Are They More Efficient Against the Arising Viral Variants? An Opinion Article’.  		 			N El-Baky 		,  		 			A A Amara 		.  	 	 		\textit{Frontiers in Medicine}  		2022. 9 p. 903876.  	 
\bibitem[Bento ()]{b14}\label{b14} 	 		‘Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity’.  		 			D Bento 		.  	 	 		\textit{European Journal of Pharmaceutics and Biopharmaceutics}  		2015. 93 p. .  	 
\bibitem[Habel ()]{b29}\label{b29} 	 		‘Effect on immunity to challenge and antibody response of variation in dosage schedule of rabies vaccine in mice’.  		 			K Habel 		.  	 	 		\textit{Bull World Health Organ}  		1956. 14  (4)  p. .  	 
\bibitem[Chen ()]{b19}\label{b19} 	 		‘Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study’.  		 			N Chen 		.  	 	 		\textit{The Lancet}  		2020. 10223. 395 p. .  	 
\bibitem[Jiang ()]{b34}\label{b34} 	 		‘Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen’.  		 			M Jiang 		.  	 	 		\textit{Frontiers in Immunology}  		2021. 12.  	 
\bibitem[Amara ()]{b9}\label{b9} 	 		‘Evaluation the surface antigen of the Salmonella typhimurium ATCC 14028 ghosts prepared by "SLRP’.  		 			A A A F Amara 		.  	 	 		\textit{The Scientific World Journal}  		2014. 2014.  	 
\bibitem[Singh ()]{b51}\label{b51} 	 		‘Evolutionary trajectory of SARS-CoV-2 and emerging variants’.  		 			J Singh 		.  	 	 		\textit{Virology Journal}  		2021. 18  (1) .  	 
\bibitem[Mortellaro and Ricciardi-Castagnoli ()]{b45}\label{b45} 	 		‘From vaccine practice to vaccine science: the contribution of human immunology to the prevention of infectious disease’.  		 			A Mortellaro 		,  		 			P Ricciardi-Castagnoli 		.  	 	 		\textit{Immunology \&amp}  		2011. 89  (3)  p. .  	 	 (Cell Biology) 
\bibitem[Chen ()]{b20}\label{b20} 	 		‘Gastrointestinal Involvement in SARS-CoV-2 Infection’.  		 			T H Chen 		.  	 	 		\textit{Viruses}  		2022. 14  (6) .  	 
\bibitem[Lauring and Hodcroft ()]{b38}\label{b38} 	 		‘Genetic Variants of SARS-CoV-2-What Do They Mean?’.  		 			A S Lauring 		,  		 			E B Hodcroft 		.  	 	 		\textit{JAMA}  		2021. 325 p. .  	 
\bibitem[Blanco-Melo ()]{b15}\label{b15} 	 		‘Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19’.  		 			D Blanco-Melo 		.  	 	 		\textit{Cell}  		2020. e1039. 181  (5)  p. .  	 
\bibitem[Fage ()]{b28}\label{b28} 	 		‘Influenza A (H1N1)pdm09 Virus but Not Respiratory Syncytial Virus Interferes with SARS-CoV-2 Replication during Sequential Infections in Human Nasal Epithelial Cells’.  		 			C Fage 		.  	 	 		\textit{Viruses}  		2022. 14  (2) .  	 
\bibitem[Diamond and Kanneganti ()]{b24}\label{b24} 	 		‘Innate immunity: the first line of defense against SARS-CoV-2’.  		 			M S Diamond 		,  		 			T.-D Kanneganti 		.  	 	 		\textit{Nature Immunology}  		2022. 23 p. .  	 
\bibitem[Amara ()]{b4}\label{b4} 	 		\textit{Kostenlos viral ghosts, bacterial ghosts microbial ghosts and more},  		 			A A Amara 		.  		2015. Schuling Verlag -Germany.  	 
\bibitem[Aguila ()]{b3}\label{b3} 	 		‘Letter: role of probiotics in the COVID-19 pandemic’.  		 			E J T Aguila 		.  	 	 		\textit{Alimentary Pharmacology \& Therapeutics}  		2020. 52  (5)  p. .  	 
\bibitem[Barrett ()]{b12}\label{b12} 	 		‘Monograph Rinderpest and peste des petits ruminants: virus plagues of large and small ruminants’.  		 			T Barrett 		.  	 	 		\textit{Series: Biology of Animal Infections}  		P.-P. Pastoret, (ed.)  		2005. Academic Press.  	 	 (series editor)) 
\bibitem[El-Baky and Amara ()]{b27}\label{b27} 	 		‘Newcastle disease virus (LaSota strain) as a model for virus Ghosts preparation using H2O2 bio-critical concentration’.  		 			N A El-Baky 		,  		 			A A Amara 		.  	 	 		\textit{International Science and Investigation Journal}  		2014. 3 p. .  	 
\bibitem[Balta ()]{b11}\label{b11} 	 		\textit{Novel Insights into the Role of Probiotics in Respiratory Infections, Allergies, Cancer, and Neurological Abnormalities},  		 			I Balta 		.  		2021. 9 p. 60.  	 
\bibitem[Mulligan ()]{b47}\label{b47} 	 		‘Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults’.  		 			M J Mulligan 		.  	 	 		\textit{Nature}  		2020. 586  (7830)  p. .  	 
\bibitem[Amara and Salem-Bekhit ()]{b8}\label{b8} 	 		‘Plackett-Burman randomization method for bacterial ghosts preparation form E. coli JM109’.  		 			A A Amara 		,  		 			M M Salem-Bekhit 		,  		 			Alanazi 		,  		 			FK 		.  	 	 		\textit{Saudi Pharmaceutical Journal}  		2014. 22 p. .  	 
\bibitem[Lopez-Santamarina ()]{b43}\label{b43} 	 		‘Probiotic Effects against Virus Infections: New Weapons for an Old War’.  		 			A Lopez-Santamarina 		.  	 	 		\textit{Foods}  		2021. 10  (1)  p. 130.  	 
\bibitem[El-Baky ()]{b2}\label{b2} 	 		‘Protein and DNA isolation from Aspergillus niger as well as ghost cells formation’.  		 			Abd El-Baky 		,  		 			N 		.  	 	 		\textit{SOJ Biochem}  		2018. 4  (1)  p. .  	 
\bibitem[Klocke ()]{b36}\label{b36} 	 		\textit{Respiration, human., Encyclopaedia Britannica Student and Home Edition. Chicago: Encyclopaedia Britannica},  		 			R A Klocke 		.  		2013.  	 
\bibitem[Amara ()]{b5}\label{b5} 	 		‘Saccharomyces cerevisiae Ghosts Using the Sponge-Like Re-Reduced Protocol’.  		 			A A Amara 		.  	 	 		\textit{SOJ Biochemistry}  		2015. p. .  	 
\bibitem[Walsh ()]{b55}\label{b55} 	 		\textit{Safety and Immunogenicity of Two RNA-Based Covid-19},  		 			E E Walsh 		.  		2020.  	 
\bibitem[Burke ()]{b16}\label{b16} 	 		‘SARS-CoV-2 infection triggers widespread host mRNA decay leading to an mRNA export block’.  		 			J M Burke 		.  	 	 		\textit{RNA}  		2021. 27  (11)  p. .  	 
\bibitem[Sui ()]{b52}\label{b52} 	 		‘SARS-CoV-2 Membrane Protein Inhibits Type I Interferon Production through Ubiquitin-Mediated Degradation of TBK1’.  		 			L Sui 		.  	 	 		\textit{Frontiers in Immunology}  		2021. 12 p. .  	 
\bibitem[Low ()]{b44}\label{b44} 	 		‘SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion’.  		 			Z Y Low 		.  	 	 		\textit{Viruses}  		2022. 14  (9) .  	 
\bibitem[Chen ()]{b18}\label{b18} 	 		‘SARS-CoV-2 Nucleocapsid Protein Interacts with RIG-I and Represses RIG-Mediated IFN-? Production’.  		 			K Chen 		.  	 	 		\textit{Viruses}  		2020. 13  (1)  p. 47.  	 
\bibitem[Wu ()]{b58}\label{b58} 	 		‘SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2’.  		 			L Wu 		.  	 	 		\textit{Signal Transduct. Target. Ther}  		2022. 7 p. 8.  	 
\bibitem[Konno ()]{b37}\label{b37} 	 		‘SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant’.  		 			Y Konno 		.  	 	 		\textit{Cell reports}  		2020. 32  (12)  p. .  	 
\bibitem[Han ()]{b30}\label{b30} 	 		\textit{SARS-CoV-2 ORF9b Antagonizes Type I and III Interferons by Targeting Multiple Components of RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING Signaling Pathways},  		 			L Han 		.  		2020.  		 			Cold Spring Harbor Laboratory 		 	 
\bibitem[Amara et al. ()]{b7}\label{b7} 	 		‘Sponge-like: a new protocol for preparing bacterial ghosts’.  		 			A A Amara 		,  		 			M M Salem-Bekhit 		,  		 			F K Alanazi 		.  		 ID 545741.  	 	 		\textit{The Scientific World Journal V}  		2013. 1013 p. 7.  	 
\bibitem[Azagra-Boronat ()]{b10}\label{b10} 	 		‘Strain-Specific Probiotic Properties of Bifidobacteria and Lactobacilli for the Prevention of Diarrhea Caused by Rotavirus in a Preclinical Model’.  		 			I Azagra-Boronat 		.  	 	 		\textit{Nutrients}  		2020. 12  (2)  p. 498.  	 
\bibitem[El-Baky ()]{b1}\label{b1} 	 		‘The Minimum Inhibition and Growth Concentrations for Controlling Fungal Infections as well as Ghost Cells Preparation: Aspergillus flavus as a Model’.  		 			Abd El-Baky 		,  		 			N 		.  	 	 		\textit{Biomedical Journal}  		2018. 1 p. 5.  	 
\bibitem[Li ()]{b41}\label{b41} 	 		‘The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway’.  		 			J.-Y Li 		.  	 	 		\textit{Virus research}  		2020. 286 p. .  	 
\bibitem[Hossain ()]{b31}\label{b31} 	 		‘Unique mutations in SARS-CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion’.  		 			A Hossain 		.  	 	 		\textit{Microb Pathog}  		2022. 170 p. 105699.  	 
\bibitem[Plummer]{b49}\label{b49} 	 		‘US Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Epsilon Variant: Highly Transmissible but with an Adjusted Muted Host T-Cell Response’.  		 			J T Plummer 		.  	 	 		\textit{Clin Infect Dis}  		 	 
\bibitem[Baud ()]{b13}\label{b13} 	 		‘Using Probiotics to Flatten the Curve of Coronavirus Disease COVID-2019 Pandemic’.  		 			D Baud 		.  	 	 		\textit{Frontiers in Public Health}  		2020. 8.  	 
\bibitem[Vaccine Candidates New England Journal of Medicine]{b56}\label{b56} 	 		‘Vaccine Candidates’.  	 	 		\textit{New England Journal of Medicine}  		383  (25)  p. .  	 
\bibitem[Amara ()]{b6}\label{b6} 	 		‘Vaccines against Pathogens: A Review and Food For Thought’.  		 			A A Amara 		.  	 	 		\textit{SOJ Biochem}  		2016. 2  (2)  p. 20.  	 
\bibitem[Pastoret and Jones (2004)]{b48}\label{b48} 	 		‘Veterinary vaccines for animal and public health’.  		 			P P Pastoret 		,  		 			P Jones 		.  	 	 		\textit{Control of infectious animal diseases by vaccination},  				 			A Schudel,  			\& M Lombard 		 (ed.)  		 (Buenos Aires, Argentina)  		2004. April. 119 p. .  	 	 (Proc. OIE Conference) 
\end{bibitemlist}
 			 		 	 
\end{document}
